REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), Virginia Martínez-Marín(Hospital Universitario La Paz), Claudia Valverde(Vall d'Hebron Hospital Universitari), David S. Moura(Hospital Universitario Fundación Jiménez Díaz), Nadia Hindi(Hospital Universitario Fundación Jiménez Díaz), Javier Martínez‐Trufero(Hospital Universitario Miguel Servet), Angelo Paolo Dei Tos(University of Padua), Marta Martín‐Ruíz(University of Pittsburgh), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Ana Vallejo‐Benítez(Hospital Regional Universitario de Málaga), Giovanni Grignani(Candiolo Cancer Institute), César Serrano(Vall d'Hebron Institut de Recerca), Elena Fumagalli(Fondazione IRCCS Istituto Nazionale dei Tumori), María Monteagudo(Spanish National Cancer Research Centre), François Le Loarer(Institut Bergonié), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Ricardo González‐Cámpora(Hospital Quirónsalud Barcelona), Javier Lavernia(Fundación Instituto Valenciano de Oncología), Bruno Vincenzi(Campus Bio Medico University Hospital), Antonio Fernández‐Serra(Fundación Instituto Valenciano de Oncología), Diana Hernández-Jover(Hospital de Sant Pau), José Antonio López‐Guerrero(Consejo Superior de Investigaciones Científicas), Rafael Ramos(Hospital Universitario Son Espases), Rocío Letón, Julia Cruz(Fundación Instituto Valenciano de Oncología), Antonio Gutiérrez(Hospital Universitario Son Dureta)
Cited by 27
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k